SB 339: Medi-Cal: laboratory rates.
- Session Year: 2025-2026
- House: Senate
- Latest Version Date: 2025-04-09
Current Status:
Failed
(2026-02-02: Returned to Secretary of Senate pursuant to Joint Rule 56.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions.
Existing law prohibits Medi-Cal reimbursement to providers for clinical laboratory or laboratory services from exceeding the lowest of the following: (1) the amount billed; (2) the charge to the general public; (3) 100% of the lowest maximum allowance established by the federal Medicare Program; or (4) a reimbursement rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying.
This bill would instead require the above-described Medi-Cal reimbursement to equal the lowest of those metrics. The bill would carve out, from the above-described provision, for dates of service on or after July 1, 2027, or when funding is appropriated to implement this provision, whichever is sooner, Medi-Cal reimbursement to providers for clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections, and would apply the above-described that threshold but excluding the reimbursement rate described in paragraph (4). The clause (4) above.
The bill would exempt data on those services related to the diagnosis and treatment of sexually transmitted infections from certain data-reporting requirements that are applicable to the reimbursement rate described in paragraph (4). clause (4), for dates of service on or after January 1, 2027, or when funding is appropriated to implement the above-described provision, whichever is sooner.
Under existing law, data reports provided to the department pursuant to those data-reporting requirements are confidential and exempt from disclosure under the California Public Records Act.
This bill would require the department to make available to the public a dataset, as specified, of the deidentified raw data reported pursuant to the above-described data-reporting requirements by any applicable laboratory service providers that reported a volume greater than 10 tests for the data-collection period. The bill would require the department to publish the associated dataset coincident with publishing updated reimbursement rates.
Existing law requires, with exceptions, exemptions, that payments be reduced by up to 10% for clinical laboratory or laboratory services, in addition to other specified payment reductions under other existing law.
This bill would delete that 10% payment reduction.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions.
Existing law prohibits Medi-Cal reimbursement to providers for clinical laboratory or laboratory services from exceeding the lowest of the following: (1) the amount billed; (2) the charge to the general public; (3) 100% of the lowest maximum allowance established by the federal Medicare Program; or (4) a reimbursement rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying.
This bill would carve out, from the above-described provision, Medi-Cal reimbursement to providers for clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections, and would apply the above-described threshold but excluding the reimbursement rate described in paragraph (4). The bill would exempt data on those services from certain data-reporting requirements that are applicable to the reimbursement rate described in paragraph (4).
Under existing law, data reports provided to the department pursuant to those data-reporting requirements are confidential and exempt from disclosure under the California Public Records Act.
This bill would require the department to make available to the public a dataset, as specified, of the deidentified raw data reported pursuant to the above-described data-reporting requirements by any applicable laboratory service providers that reported a volume greater than 10 tests for the data-collection period. The bill would require the department to publish the associated dataset coincident with publishing updated reimbursement rates.
Existing law requires, with exceptions, that payments be reduced by up to 10% for clinical laboratory or laboratory services, in addition to other specified payment reductions under other existing law.
This bill would delete that 10% payment reduction.
(a)(1)It is the intent of the Legislature that the department develop reimbursement rates for clinical laboratory or laboratory services that are comparable to the payment amounts received from other payers for clinical laboratory or laboratory services. Development of these rates will enable the department to reimburse clinical laboratory or laboratory service providers in compliance with state and federal law.
(2)(A)The requirements specified in subdivision (a) of Section 51501 of Title 22 of the California Code of Regulations shall not apply to laboratory providers reimbursed under the new rate methodology developed for clinical laboratories or laboratory services pursuant to this subdivision.
(B)In addition to subparagraph (A), laboratory providers reimbursed under any payment reductions implemented pursuant to this section shall not be subject to the requirements specified in subdivision (a) of Section 51501 of Title 22 of the California Code of Regulations until July 1, 2015.
(3)(A)Reimbursement to providers for clinical laboratory or laboratory services, except those clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections, shall not exceed the lowest of the following:(3)(A)Except as described in subparagraph (B), reimbursement to providers for clinical laboratory or laboratory services shall equal the lowest of the following:
(i)The amount billed.
(ii)The charge to the general public.
(iii)One hundred percent of the lowest maximum allowance established by the federal Medicare Program for the same or similar services.
(iv)A reimbursement rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar clinical laboratory or laboratory services.
(B)Reimbursement Notwithstanding subparagraph (A), for dates of service on or after July 1, 2027, or when funding is appropriated to implement this subparagraph, whichever is sooner, reimbursement to providers for clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections shall not exceed equal the lowest of the following:
(i)The amount billed.
(ii)The charge to the general public.
(iii)One hundred percent of the lowest maximum allowance established by the federal Medicare Program for the same or similar services.
(4)(A)For purposes of establishing reimbursement rates for clinical laboratory or laboratory services pursuant to clause (iv) of subparagraph (A) of paragraph (3), laboratory service providers shall submit data reports according to the following schedule:
(i)The data initially provided shall be for the 2018 calendar year. For each subsequent reporting year, the data shall be based on the previous calendar year.
(ii)For purposes of clause (i), reporting year means 2019 and every third year thereafter.
(B)In accordance with subparagraph (B) of paragraph (3), data Data on clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections shall be exempt from the data reporting specified in this section. paragraph, for dates of service on or after January 1, 2027, or when funding is appropriated to implement subparagraph (B) of paragraph (3), whichever is sooner.
(C)A data report submitted pursuant to subparagraph (A) shall specify the providers lowest amounts other payers are paying, including other state Medicaid programs and private insurance, minus discounts and rebates. The specific data required for submission under this subparagraph and the format for the data submission shall be determined and specified by the department after receiving stakeholder input pursuant to paragraph (6).
(D)The data submitted pursuant to subparagraph (A) may be used to determine reimbursement rates by procedure code based on an average of the lowest amount other payers are paying providers for similar clinical laboratory or laboratory services, excluding significant deviations of cost or volume factors and with consideration to geographical areas. The department shall have the discretion to determine the specific methodology and factors used in the development of the lowest average amount under this subparagraph to ensure compliance with federal Medicaid law and regulations as specified in paragraph (8).
(E)For purposes of subparagraph (D), the department may contract with a vendor for the purposes of collecting payment data reports from clinical laboratories, analyzing payment information, and calculating a proposed rate.
(F)The proposed rates calculated by the vendor, as described in subparagraph (E), may be used in determining the lowest reimbursement rate for clinical laboratories or laboratory services in accordance with subparagraph (A) of paragraph (3).
(G)Data reports submitted to the department shall be certified by the providers certified financial officer or an authorized individual.
(H)Clinical laboratory providers that fail to submit data reports within 30 working days from the time requested by the department shall be subject to the suspension standards of subdivisions (a) and (c) of Section 14123.
(5)(A)Data reports provided to the department pursuant to this section shall be confidential and shall be exempt from disclosure under the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code).
(B)Notwithstanding subparagraph (A), the department shall make available to the public a dataset of the deidentified raw data reported pursuant to subparagraph (A) of paragraph (4) by any applicable laboratory service providers that reported a volume greater than 10 tests for the data-collection period. The dataset shall include Healthcare Common Procedure Coding System (HCPCS) codes, third-party payer rates, and associated volumes of tests furnished. The department shall publish the associated dataset coincident with publishing updated reimbursement rates pursuant to paragraph (3).
(6)The department shall seek stakeholder input on the ratesetting methodology.
(7)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement this section, in whole or in part, by means of provider bulletins or notices, policy letters, or other similar instructions, without taking any further regulatory action.
(8)(A)The department shall implement this section in a manner that is consistent with federal Medicaid law and regulations. The director shall seek any necessary federal approvals for the implementation of this section. This section shall be implemented only to the extent that federal approvals are obtained and federal financial participation is available and is not otherwise jeopardized.
(B)In determining whether federal financial participation is available, the director shall determine whether the rates and payments comply with applicable federal Medicaid requirements, including those set forth in Section 1396a(a)(30)(A) of Title 42 of the United States Code.
(C)To the extent that the director determines that the rates and payments do not comply with applicable federal Medicaid requirements or that federal financial participation is not available with respect to any reimbursement rate, the director retains the discretion not to implement that rate or payment and may revise the rate or payment as necessary to comply with federal Medicaid requirements. The department shall notify the Joint Legislative Budget Committee 10 days prior to revising the rate or payment to comply with federal Medicaid requirements.
(b)Reimbursement rates developed pursuant to clause (iv) of subparagraph (A) of paragraph (3) of subdivision (a) and the changes made by the act that added this subdivision shall be effective beginning on July 1, 2020, and on July 1 of every third year thereafter.
(c)Notwithstanding subdivisions (a) and (b), for dates of service from July 1, 2021, to June 30, 2022, inclusive, the department shall establish the reimbursement rates for clinical laboratory or laboratory services at the rates in effect and approved in the Medi-Cal State Plan as of December 31, 2019, pursuant to Section 14105.222.
(a)(1)It is the intent of the Legislature that the department develop reimbursement rates for clinical laboratory or laboratory services that are comparable to the payment amounts received from other payers for clinical laboratory or laboratory services. Development of these rates will enable the department to reimburse clinical laboratory or laboratory service providers in compliance with state and federal law.
(2)(A)The requirements specified in subdivision (a) of Section 51501 of Title 22 of the California Code of Regulations shall not apply to laboratory providers reimbursed under the new rate methodology developed for clinical laboratories or laboratory services pursuant to this subdivision.
(B)In addition to subparagraph (A), laboratory providers reimbursed under any payment reductions implemented pursuant to this section shall not be subject to the requirements specified in subdivision (a) of Section 51501 of Title 22 of the California Code of Regulations until July 1, 2015.
(3)(A)Reimbursement to providers for clinical laboratory or laboratory services services, except those clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections, shall not exceed the lowest of the following:
(A)(i)The amount billed.
(B)(ii)The charge to the general public.
(C)(i)For dates of service before July 1, 2022, 80 percent of the lowest maximum allowance established by the federal Medicare program for the same or similar services.(ii)For dates of service on or after July 1, 2022, 100 percent(iii)One hundred percent of the lowest maximum allowance established by the federal Medicare program Program for the same or similar services.
(D)(iv)A reimbursement rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar clinical laboratory or laboratory services.
(4)(A)In addition to the payment reductions implemented pursuant to Section 14105.192, payments shall be reduced by up to 10 percent for clinical laboratory or laboratory services, as defined in Section 51137.2 of Title 22 of the California Code of Regulations, for dates of service on and after July 1, 2012. The payment reductions pursuant to this paragraph shall continue until the new rate methodology under this subdivision has been approved by the federal Centers for Medicare and Medicaid Services.(B)Notwithstanding subparagraph (A), the Family Planning, Access, Care, and Treatment Program pursuant to subdivision (aa) of Section 14132 shall be exempt from the payment reduction specified in this section.(B)Reimbursement to providers for clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections shall not exceed the lowest of the following:
(i)The amount billed.
(ii)The charge to the general public.
(iii)One hundred percent of the lowest maximum allowance established by the federal Medicare Program for the same or similar services.
(5)(4)(A)For purposes of establishing reimbursement rates for clinical laboratory or laboratory services pursuant to subparagraph (D) clause (iv) of subparagraph (A) of paragraph (3), laboratory service providers shall submit data reports according to the following schedule:
(i)The data initially provided shall be for the 2018 calendar year. For each subsequent reporting year, the data shall be based on the previous calendar year.
(ii)For purposes of clause (i), reporting year means 2019 and every third year thereafter.
(B)In accordance with subparagraph (B) of paragraph (3), data on clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections shall be exempt from the data reporting specified in this section.
(B)(C)A data report submitted pursuant to subparagraph (A) shall specify the providers lowest amounts other payers are paying, including other state Medicaid programs and private insurance, minus discounts and rebates. The specific data required for submission under this subparagraph and the format for the data submission shall be determined and specified by the department after receiving stakeholder input pursuant to paragraph (7). (6).
(C)(D)The data submitted pursuant to subparagraph (A) may be used to determine reimbursement rates by procedure code based on an average of the lowest amount other payers are paying providers for similar clinical laboratory or laboratory services, excluding significant deviations of cost or volume factors and with consideration to geographical areas. The department shall have the discretion to determine the specific methodology and factors used in the development of the lowest average amount under this subparagraph to ensure compliance with federal Medicaid law and regulations as specified in paragraph (9). (8).
(D)(E)For purposes of subparagraph (C), (D), the department may contract with a vendor for the purposes of collecting payment data reports from clinical laboratories, analyzing payment information, and calculating a proposed rate.
(E)(F)The proposed rates calculated by the vendor, as described in subparagraph (D), (E), may be used in determining the lowest reimbursement rate for clinical laboratories or laboratory services in accordance with subparagraph (A) of paragraph (3).
(F)(G)Data reports submitted to the department shall be certified by the providers certified financial officer or an authorized individual.
(G)(H)Clinical laboratory providers that fail to submit data reports within 30 working days from the time requested by the department shall be subject to the suspension standards of subdivisions (a) and (c) of Section 14123.
(6)(5)(A)Data reports provided to the department pursuant to this section shall be confidential and shall be exempt from disclosure under the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code).
(B)Notwithstanding subparagraph (A), the department shall make available to the public a dataset of the deidentified raw data reported pursuant to subparagraph (A) of paragraph (4) by any applicable laboratory service providers that reported a volume greater than 10 tests for the data-collection period. The dataset shall include Healthcare Common Procedure Coding System (HCPCS) codes, third-party payer rates, and associated volumes of tests furnished. The department shall publish the associated dataset coincident with publishing updated reimbursement rates pursuant to paragraph (3).
(7)(6)The department shall seek stakeholder input on the ratesetting methodology.
(8)(7)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement this section, in whole or in part, by means of provider bulletins or notices, policy letters, or other similar instructions, without taking any further regulatory action.
(9)(8)(A)The department shall implement this section in a manner that is consistent with federal Medicaid law and regulations. The director shall seek any necessary federal approvals for the implementation of this section. This section shall be implemented only to the extent that federal approvals are obtained and federal financial participation is available and is not otherwise jeopardized.
(B)In determining whether federal financial participation is available, the director shall determine whether the rates and payments comply with applicable federal Medicaid requirements, including those set forth in Section 1396a(a)(30)(A) of Title 42 of the United States Code.
(C)To the extent that the director determines that the rates and payments do not comply with applicable federal Medicaid requirements or that federal financial participation is not available with respect to any reimbursement rate, the director retains the discretion not to implement that rate or payment and may revise the rate or payment as necessary to comply with federal Medicaid requirements. The department shall notify the Joint Legislative Budget Committee 10 days prior to revising the rate or payment to comply with federal Medicaid requirements.
(b)Reimbursement rates developed pursuant to subparagraph (D) clause (iv) of subparagraph (A) of paragraph (3) of subdivision (a) and the changes made by the act that added this subdivision shall be effective beginning on July 1, 2020, and on July 1 of every third year thereafter.
(c)Notwithstanding subdivisions (a) and (b), for dates of service from July 1, 2021, to June 30, 2022, inclusive, the department shall establish the reimbursement rates for clinical laboratory or laboratory services at the rates in effect and approved in the Medi-Cal State Plan as of December 31, 2019, pursuant to Section 14105.222.
|
Date
|
Status
|
|---|---|
| Feb 2, 2026 | Returned to Secretary of Senate pursuant to Joint Rule 56. |
| May 23, 2025 | May 23 hearing: Held in committee and under submission. |
| May 16, 2025 | Set for hearing May 23. |
| May 12, 2025 | May 12 hearing: Placed on APPR. suspense file. |
| May 2, 2025 | Set for hearing May 12. |
| Apr 30, 2025 | From committee: Do pass and re-refer to Com. on APPR. with recommendation: To consent calendar. (Ayes 13. Noes 0. Page 939.) (April 29). Re-referred to Com. on APPR. |
| Apr 24, 2025 | From committee: Do pass and re-refer to Com. on JUD. (Ayes 11. Noes 0. Page 868.) (April 23). Re-referred to Com. on JUD. |
| Apr 10, 2025 | Set for hearing April 29 in JUD. pending receipt. |
| Apr 9, 2025 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Apr 8, 2025 | Set for hearing April 23. |
| Apr 2, 2025 | April 2 hearing postponed by committee. |
| Mar 17, 2025 | Set for hearing April 2. |
| Feb 19, 2025 | Referred to Coms. on HEALTH and JUD. |
| Feb 13, 2025 | From printer. May be acted upon on or after March 15. |
| Feb 12, 2025 | Introduced. Read first time. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| May 12, 2025 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 29, 2025 | Do pass, but first be re-referred to the Committee on [Appropriations] with the recommendation: To Consent Calendar | Senate Standing Committee on Judiciary |
Passed |
|
| Apr 23, 2025 | Do pass, but first be re-referred to the Committee on [Judiciary] | Senate Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| American College Of Obstetricians Gynecologists District Ix | ** Support | |
| APLA Health | ** Support | |
| BIPOC Student Midwives Fund | ** Support | |
| California Clinical Laboratory Association | ** Support | |
| California Latinas for Reproductive Justice | ** Support | |
| CALIFORNIA PRIMARY CARE ASSOCIATION ADVOCATES | ** Support | |
| California Society Of Pathologists | ** Support | |
| Community Clinic Association of Los Angeles County | ** Support | |
| Community Health Association of Inland Southern Region | ** Support | |
| Council of Community Clinics | ** Support | |
| Equality California | ** Support | |
| Essential Access Health | ** Support | |
| Los Angeles LGBT Center | ** Support | |
| Planned Parenthood Affiliates Of California | ** Support | |
| The BIPOC Student Midwives Fund | ** Support |
SENATE COMMITTEE ON
Senator Anna Caballero, Chair
2025 - 2026 Regular Session
SB 339 (Cabaldon) - Medi-Cal: laboratory rates
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
SB 339 would make changes to Medi-Cal laboratory rates, as specified.
Fiscal Impact:
- Unknown ongoing costs, likely hundreds of thousands, for the Department of Health Care Services (DHCS) for state administration (General Fund and federal funds).
- Unknown ongoing costs due to increased Medi-Cal rates for clinical laboratory or laboratory services (General Fund and federal funds).
Background:
The Medi-Cal program provides health care services to qualified low-income individuals. The Medi-Cal program’s schedule of benefits includes outpatient laboratory services, subject to utilization controls. Current law requires that reimbursement to providers for clinical laboratory or laboratory services not exceed the lowest of the following:
- The amount billed.
- The charge to the general public.
- 100 percent of the lowest maximum allowance established by the federal Medicare program for the same or similar services.
- A reimbursement rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar clinical laboratory or laboratory services.
For purposes of establishing reimbursement rates (pursuant to the above provision related to calculating the rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying for clinical laboratory or laboratory services) laboratory service providers must submit data reports to DHCS. The data reports must specify the provider’s lowest amounts other payers are paying, including other state Medicaid programs and private insurance, minus discounts and rebates.
Proposed Law:
Specific provisions of the bill would:
- Require that, for dates of service on or after July 1, 2027, or when funding is appropriated to implement this provision, whichever is sooner, reimbursement to providers for clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections must equal the lowest of the following:
- The amount billed.
- The charge to the general public.
- 100 percent of the lowest maximum allowance established by the federal Medicare Program for the same or similar services.
- Exempt data on clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections from the data reporting, for dates of service on or after January 1, 2027, or when funding is appropriated to implement the above provision, whichever is sooner.
- Require DHCS to make available to the public a dataset of the deidentified raw data reported by any applicable laboratory service providers that reported a volume greater than 10 tests for the data-collection period, as specified.
-- END --
Senator Thomas Umberg, Chair
2025-2026 Regular Session
Bill No: SB 339 (Author:Cabaldon)
Version: April 9, 2025
Hearing Date: April 29, 2025
Fiscal: Yes
Urgency: No
AMConsultant:
SUBJECT
Medi-Cal: laboratory rates
DIGEST
This bill increases Medi-Cal reimbursement rates for clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections (STIs) for services on or after July 1, 2027, or upon appropriation for this purpose, whichever occurs first, as specified. The bill provides that reimbursement rates for all other clinical laboratory or laboratory services are to equal, instead of not exceed, the lowest of existing reimbursement criteria. The bill requires the Department of Health Care Services (DHCS) to make available to the public a dataset of the deidentified raw data reported under existing law by laboratory service providers, as specified.
EXECUTIVE SUMMARY
This bill seeks to increases Medi-Cal reimbursement rates for clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections (STIs). The bill also provides public transparency into how DHCS calculates reimbursement rates for clinical laboratory or laboratory services. The author, sponsor, and supporters of the bill state that in the past 5 years, California has been experiencing unprecedented, epidemic levels of STIs. They argue it is imperative that Medi-Cal reimbursement rates increase so providers can continue to offer vital STI testing.
The bill is sponsored by Planned Parenthood Affiliates of California. The bill is supported by various organizations representing healthcare practitioners and healthcare clinics, and advocates for the LGBTQ community. No timely opposition was received by the Committee. The bill passed the Senate Health Committee on a vote of 11 to 0.
PROPOSED CHANGES TO THE LAW
Existing law:
- Establishes the Medi-Cal program, administered by the Department of Health Care Services (DHCS), under which health care services are provided to qualified low-income persons. (Welf. & Inst. Code §§ 14000 et seq.)
- Establishes a schedule of benefits under the Medi-Cal program, which includes outpatient laboratory services. (Welf. & Inst. Code § 14132.)
- Requires reimbursement for clinical laboratory or laboratory services not to exceed the lowest of the following:
- the amount billed;
- the charge to the general public;
- 100 percent of the lowest maximum allowance established by the federal Medicare Program (Medicare) for the same or similar services for dates of service on or after July 1, 2022; or
- a reimbursement rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar clinical laboratory or laboratory services. (Welf. & Inst. Code § 14105.22(a)(3).)
- Requires laboratory service providers, for purposes of establishing a reimbursement rate in 3)d), above, to submit data reports every three years. (Welf. & Inst. Code § 14105.22(a)(5).)
- Requires these developed reimbursement rates to become operative beginning on July 1, 2020, and on July 1 of every third year thereafter. (Welf. & Inst. Code § 14105.22(b).)
- Data reports provided to the DHCS are confidential and exempt from disclosure under the California Public Records Act (CPRA). (Welf. & Inst. Code § 14105.22(a)(6).)
This bill:
- Requires reimbursement for clinical laboratory or laboratory services to equal, instead of not exceed, the lowest of the following:
- the amount billed;
- the charge to the general public;
- 100 percent of the lowest maximum allowance established by the federal Medicare Program (Medicare) for the same or similar services for dates of service on or after July 1, 2022; or
- a reimbursement rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar clinical laboratory or laboratory services.
- Requires, for services on or after July 1, 2027, or when funding is appropriated to implement this provision, whichever occurs first, that reimbursement rates to providers for clinical laboratory or laboratory services related to the diagnosis and treatment of STIs are to equal the lowest of the following:
- the amount billed;
- the charge to the general public; or
- 100 percent of the lowest maximum allowance established by the federal Medicare Program for the same or similar services.
- Provides that data on clinical laboratory or laboratory services related to the diagnosis and treatment of STIs is exempt from the data reporting requirement for services on or after January 1, 2027, or when funding is appropriated to implement 2), above, whichever is sooner.
- Requires DHCS to make available to the public a dataset of the deidentified raw data required to be reported by any applicable laboratory service providers that reported a volume greater than 10 tests for the data-collection period.
- The dataset is to include Healthcare Common Procedure Coding System (HCPCS) codes, third-party payer rates, and associated volumes of tests furnished
- DHCS is required publish the associated dataset coincident with publishing updated reimbursement rates.
COMMENTS
- Stated need for the bill
The author writes:
California is experiencing epidemic levels of sexually transmitted infections (STIs) which, left untreated, can lead to serious health complications. STIs are preventable through regular testing and timely treatment. Ensuring that these services are accessible, especially to our state’s most vulnerable populations, is critical to ending California’s STI epidemic. Unfortunately, community health centers and those that serve Medi-Cal recipients face unsustainably low reimbursement rates for STI testing, impacting their ability to provide necessary care.
SB 339 addresses this issue by guaranteeing fair reimbursement rates for STI testing, helping to ensure that low-income Californians continue to have access to these vital services. Currently, Medi-Cal rates for STI testing are adjusted on a triannual basis based on the lowest average of commercial rate for testing, not to exceed 100% of Medicare. Intended to keep Medi-Cal costs low, the triannual review process has instead resulted in retroactive clawbacks of reimbursements and rate uncertainty, leaving community health centers scrambling to support their low-income patients. SB 339 will exempt STI testing and treatment from the triannual review process and cap reimbursement at the lowest maximum Medicare allowance.
- Medi-Cal reimbursement rates for clinical laboratory or laboratory services
The author, sponsor, and supporters of the bill claim that “California has seen unprecedented epidemic levels of STIs for the past 5 years.” As evidence for this, they point to data reported by the federal Centers for Disease Control and Prevention (CDC) in 2022 showing that California had the 22nd highest chlamydia rate (per 100,000 population), the 18th highest gonorrhea rate, and 11th highest rate of congenital syphilis (per 100,000 live births).[1] The DHCS reported that “[s]triking disparities in STI rates persist throughout the state, with the highest rates among Black/African Americans; men who have sex with men; and young people (15-24 years of age). People with bacterial STIs are at higher risk for related adverse health outcomes such as HIV infection, infertility, ocular, otic, and neurosyphilis, and multi-drug resistant gonorrhea, among others.”[2]
Testing is a crucial part of treating and stopping the spread of STIs, especially for vulnerable populations. Planned Parenthood Affiliates of California, the sponsor of the bill, writes:
Regular STI testing is the first step to ensuring proper diagnosis and treatment of STIs, decreasing transmission, and mitigating long term negative health impacts. For example, Planned Parenthood of Orange and San Bernardino Counties (PPOSBC) recently reported a substantial decline of 32% in early syphilis cases in cities where there is a PPOSBC health center, underscoring the impact of their STI screening efforts.
Under existing law, DHCS conducts a review of commercial reimbursement rates for clinical laboratory services, including tests for STIs, every three years. According to the author and sponsor, this review is not transparent and very often results in significant reductions to reimbursement rates for Medi-Cal providers. These reductions in rates are implemented retroactively resulting in clawbacks, which weakens the ability of providers to offer vital STI testing.
In order to address this issue the bill does several things. First, the bill exempts data on clinical laboratory or laboratory services related to the diagnosis and treatment of STIs from being reported to DHCS for dates of services on and after January 1, 2027. Second, the bill provides that clinical laboratory or laboratory services for the diagnosis or treatment of STIs are to equal the lowest of: the amount billed, the charge to the general public, 100 percent of the lowest maximum allowance under Medicare. The bill provides that this provision applies for services on and after July 1, 2027, or when funding is implemented, whichever occurs first. Third, the bill provides that for all other clinical laboratory or laboratory services, the reimbursement rate is to equal, instead of not exceed, the lowest of: the amount billed; the charge to the general public, 100 percent of the lowest maximum allowed under Medicare; or the reimbursement rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar clinical laboratory or laboratory services.
Lastly, the bill requires DHCS to make available to the public a dataset of the deidentified raw data required to be reported to DHCS by any applicable laboratory service provider that reported a volume greater than 10 tests for the data-collection period. The dataset is to include HCPCS codes, third-party payer rates, and associated volumes of tests furnished. Under the bill, DHCS is required publish this information coincident with publishing updated reimbursement rates. By requiring the data to be deidentified before being made available to the public, the bill ensures the confidentiality of any personally identifiable information that may be contained in the data set.
- Statements in support
Essential Access Health writes in support, stating:
California has seen unprecedented epidemic levels of STIs for the past 5 years. In 2022, the CDC reported that California had the 22nd highest chlamydia rate, 18th highest gonorrhea rate, and 11th highest rate of congenital syphilis, per capita. The highest STI rates continue to occur among young people (aged 15-24) and Black and LGBTQ+ individuals, particularly those assigned male at birth. People with bacterial STIs are at higher risk for related adverse health outcomes, such as infertility and multi-drug resistant gonorrhea. Racial disparities in gonorrhea persist with Black individuals experiencing infections at 2.6 times higher than the statewide rate.
Regular STI testing is the first step to ensuring proper diagnosis and treatment of STIs, decreasing transmission, and mitigating long term negative health impacts. Safety-net providers, including community health centers, offer essential STI testing and treatment services to Californians with disproportionately high rates of STIs. These providers depend on adequate Medi-Cal reimbursement rates to provide these services. However, the variable reimbursement rate process has created a challenging financial environment for safety-net providers.
SB 339 will solve this problem by excluding clinical laboratory tests for STIs from the triannual review process and setting those rates to 100% of Medicare. Essential Access is committed to supporting policies that reduce the transmission of sexually transmitted infections and expand access to preventive services, including funding for testing and treatment.
SUPPORT
Planned Parenthood Affiliates of California (sponsor)
American College of Obstetricians & Gynecologists - District IX
APLA Health
California Clinical Laboratory Association
California Latinas for Reproductive Justice
California Society of Pathologists
Council of Community Clinics
Equality California
Essential Access Health
Los Angeles LGBT Center
The BIPOC Student Midwives Fund
OPPOSITION
None received
RELATED LEGISLATION
Pending Legislation: None known.
Prior Legislation:
AB 133 (Committee on Budget, Ch. 143, Stats. 2021), among other things, required DHCS to develop, subject to federal approval, reimbursement rates for clinical or laboratory services according to specified standards.
AB 1327 (Petrie Norris 2021) would have deleted the requirement for Medi-Cal fee-for-service clinical laboratory or laboratory services reimbursement to not exceed 80 percent of the lowest maximum allowance established by Medicare for the same or similar services. The provisions of this bill were enacted in AB 133.
AB 659 (Ridley-Thomas, Ch. 346, Stats. 2017) required third-party payer data to be analyzed every three years, instead of every year, for setting reimbursement rates by DHCS.
PRIOR VOTES:
Senate Health Committee (11 Ayes, 0 Noes)
**************
Sexually Transmitted Infections in California 2022 Executive Summary, Cal. Dept. of Pub. Health at p. 3, available at https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/2022-STD-Surveillance-Executive-Summary.pdf. ↑
Id. at 1. ↑
SENATE COMMITTEE ON HEALTH
Senator Caroline Menjivar, Chair
BILL NO: SB 339
AUTHOR: | Cabaldon | ||
VERSION: | April 9, 2025 | ||
HEARING DATE: | April 23, 2025 | ||
CONSULTANT: | Jen Flory | ||
SUBJECT: Medi-Cal: laboratory rates
SUMMARY:
Exempts clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections from the portion of the rate-setting that is based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar services, starting July 1, 2027, or if funding is appropriated sooner. Exempts providers of these services from producing data to determine this amount and requires the remaining laboratory data to be made public.
Existing law:
- Establishes the Medi-Cal program, which is administered by the Department of Health Care Services (DHCS), and under which qualified low-income individuals receive health care services. [WIC §14000, et seq.]
- Establishes a schedule of benefits under the Medi-Cal program, which includes benefits required under federal law and benefits provided at the state’s option, both of which are funded with federal and state dollars. Includes in the schedule of benefits outpatient laboratory services, subject to utilization controls. [WIC §14132]
- Prohibits reimbursement to providers for clinical laboratory or laboratory (collectively “lab”) services from exceeding the lowest of the following: the amount billed, the amount charged to the general public, the lowest maximum allowance established by Medicare for the same or similar service, or a reimbursement rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar lab services.
[WIC §14105.22]
- Requires lab services providers to submit data reports every three years to specify the lowest amounts other payers are paying, including other state Medicaid programs and private insurance, minus discounts and rebates, for lab services. Lab providers that do not comply shall be subject to the rules regarding provider suspension from the Medi-Cal program. [WIC §14105.22]
- Authorizes DHCS to have discretion to determine the specific methodology and factors used in the development of the lowest average amount other payers are paying to ensure compliance with federal Medicaid law and regulations after seeking stakeholder input. [WIC §14105.22]
- Exempts the lab rate data submitted to DHCS from the California Public Records Act. [WIC §14105.22]
This bill:
- Exempts lab services related to the diagnosis and treatment of sexually transmitted infections (STIs) from the portion of the rate-setting that is based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar lab services, starting July 1, 2027, or sooner, if funding is appropriated for this purpose.
- Exempts data on lab services related to the diagnosis and treatment of STIs from the data reporting requirements described in 1) above, used in determining the lab rates, starting January 1, 2027, or sooner, if funding is appropriated for this purpose.
- Clarifies that the reimbursement to providers for lab services, including those related to the diagnosis and treatment of sexually transmitted infections, shall be based on the lowest of the factors used to determine the rate, rather than “not exceeding” the lowest of the factors used to determine the rate.
- Requires DHCS to make available to the public a dataset of deidentified raw data that is reported pursuant to the requirement in 4) above, by any applicable lab service providers that reported more than 10 tests for the data-collection period. Requires the dataset to include Healthcare Common Procedure Coding System codes, third-party payer rates, and volumes of tests furnished. Requires DHCS to publish this data when publishing the updated lab rates.
FISCAL EFFECT:
This bill has not been analyzed by a fiscal committee.
COMMENTS:
- Author’s statement. According to the author, California is experiencing epidemic levels of STIs, which left untreated, can lead to serious health complications. STIs are preventable through regular testing and timely treatment. Ensuring that these services are accessible, especially to our state’s most vulnerable populations, is critical to ending California’s STI epidemic. Unfortunately, community health centers and those that serve Medi-Cal recipients face unsustainably low reimbursement rates for STI testing, impacting their ability to provide necessary care. This bill addresses this issue by guaranteeing fair reimbursement rates for STI testing, helping to ensure that low-income Californians continue to have access to these vital services. Currently, Medi-Cal rates for STI testing are adjusted on a triannual basis based on the lowest average of commercial rate for testing, not to exceed 100% of Medicare. Intended to keep Medi-Cal costs low, the triannual review process has instead resulted in retroactive clawbacks of reimbursements and rate uncertainty, leaving community health centers scrambling to support their low-income patients. This bill will exempt STI testing and treatment from the triannual review process and cap reimbursement at the lowest maximum Medicare allowance.
- Medi-Cal Lab Reimbursement. AB 1494 (Committee on Budget, Chapter 28, Statutes of 2012), a health budget trailer bill, changed the Medi-Cal reimbursement methodology for lab services. Prior to the enactment of AB 1494, Medi-Cal reimbursement for lab services was capped at an amount that could not exceed 80% of the lowest maximum allowance established by the federal Medicare program for the same or similar services. AB 1494 stated legislative intent that DHCS develop reimbursement rates for lab services that are comparable to the payment amounts received from other payers for lab services, and capped Medi-Cal reimbursement for lab providers at an amount not to exceed the lowest of the following: the amount billed; the charge to the general public; 80% of the lowest maximum allowance established by the federal Medicare Program for the same or similar services; or, a reimbursement rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar lab services.
In addition to the new reimbursement methodology, AB 1494 imposed an additional Medi-Cal payment reduction of up to 10% in order to achieve General Fund savings (this reduction has not taken effect). In return, AB 1494 exempted labs from the Medi-Cal comparable price regulation for 12 months when the labs were subject to the additional 10% Medi-Cal rate reduction. Effective July 1, 2015, the new reimbursement methodology became applicable for certain lab service codes. AB 1494 required DHCS to update the reimbursement rates to the applicable lab service codes annually. To develop the new Medi-Cal lab rates, DHCS has had to collect rate data from lab providers and develop a new methodology based on those rate submissions. Both the formula and the frequency of collection of the data has been adjusted in subsequent legislation. AB 659 (Ridley Thomas, Chapter 346, Statutes of 2017) changed the frequency developing lab rates from every year to every three years. AB 133 (Committee on Budget, Chapter 143, Statutes of 2021) raised the Medicare maximum allowance threshold to 100%, though still requiring the comparisons to the amount billed, the amount charged, or the lowest average amount that other payers are paying.
According to the DHCS Clinical Laboratory Services Rate Methodology webpage, in March 2024 updated rates for 27 lab tests were posted. These rates approved on November 8, 2023, retroactive to July 1, 2023. While many of the tests are for STIs, other tests included are for drugs, tuberculosis, vitamin D, prostate cancer, surgical pathology, antibodies, thyroid function, liver function, insulin levels, other viral, bacterial, fungal, or parasite infections, and comprehensive metabolic tests to screen for diabetes, kidney, and liver disease. DHCS recently reported an update in preparation for the July 1, 2026 lab reimbursement rates, notifying over 300 providers to submit updated 2024 rates for over 300 lab procedure codes by June 30, 2025.
- Medi-Cal provider rate increases. The Medi-Cal program recently implemented some provider rate increases and is in the process of planning more due to the renewal of a Managed Care Organization (MCO) tax and Proposition 35, which passed in November 2024. Federal Medicaid regulations allow states to impose taxes on health care service providers to use as the non-federal share of spending for health care services in a state’s Medicaid program, which allows the state to draw down additional federal funding for those services. State Medicaid programs may receive federal financial participation for expenditures using health care-related taxes, as long as the taxes are broad-based, uniformly imposed, and contain no hold-harmless provisions. AB 119 (Committee on Budget, Chapter 13, Statutes of 2023) reauthorized a tax on MCOs licensed by the Department of Managed Health Care or contracted with the Medi-Cal program to generate funds for the Medi-Cal program, including to increase provider rates. Last year, the tax was increased to generate additional funding via SB 136 (Committee on Budget and Fiscal Review, Chapter 6, Statutes of 2024). In November, voters passed Proposition 35 to make the MCO tax permanent and allocate the majority of the revenues to provider rate increases. Total revenues from the tax have been estimated between $2 and $5 billion annually. Proposition 35 requires DHCS to consult with a stakeholder advisory committee, appointed by the Governor and Legislative leaders, prior to proposing or implementing any new provider payments or changes to existing provider payments supported by the MCO tax. The MCO tax does not specifically include lab rates. It does, however, contain broad categories that could include lab services, such as increases for outpatient and Family PACT program services.
- Double referral. This bill has been double referred. Should it pass out of this Committee, it will be referred to the Senate Judiciary Committee.
- Prior legislation. SB 136 (Committee on Budget and Fiscal Review, Chapter 6, Statutes of 2024) increased the existing MCO tax.
AB 119 (Committee on Budget, Chapter 13, Statutes of 2023) authorized an MCO tax, effective April 1, 2023 through December 31, 2026, with revenues to be used to support the Medi-Cal program, including new targeted provider rate increases.
AB 659 (Ridley Thomas, Chapter 346, Statutes of 2017) changed the frequency of developing lab rates from every year to every 3 years.
AB 1494 (Committee on Budget, Chapter 28, Statutes of 2012) implemented the rate methodology for lab rates as the lower of the amount billed, the amount charged to the general public, or 80% of the Medicare rate, and permitted an additional rate reduction of 10%.
- Support. Sponsors Planned Parenthood Affiliates of California write that the triannual review process was initially created to reduce Medi-Cal costs by ensuring the state does not pay above the lowest average commercial rate. However, the variable reimbursement rate this process has created actually results in a challenging financial environment for safety-net providers. The process is not transparent and is often implemented several months after the effective date, leaving providers doubly impacted - by both an unpredictable rate cut and a retroactive clawback of payments. They give the example of the most recent rate adjustment in spring 2024, where the triannual review of commercial rates for lab services, resulted in an 18% cut to the Medi-Cal rates for gonorrhea and chlamydia testing that was retroactively implemented to July 1, 2023. These revised Medi-Cal rates are 27.4% below current Medicare rates. For Planned Parenthood alone, this rate cut resulted in a greater than $10 million loss and a retroactive clawback of reimbursements for services provided between July 2023 and Spring 2024. Other supporters, including providers and consumer advocates make similar arguments about the need for stable and adequate reimbursement and point to a dramatic increase in STI rates in California in the last five years.
SUPPORT AND OPPOSITION:
Support: Planned Parenthood Affiliates of California (sponsor)
American College of Obstetricians & Gynecologists – District IX
APLA Health
BIPOC Student Midwives Fund
California Clinical Laboratory Association
California Latinas for Reproductive Justice
California Primary Care Association Advocates
California Society of Pathologists
Community Clinic Association of Los Angeles County
Community Health Association Inland Southern Region
Council of Community Clinics
Equality California
Essential Access Health
Los Angeles LGBT Center
Oppose: None received.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Caroline Menjivar, Chair
BILL NO: SB 339
AUTHOR: | Cabaldon | ||
VERSION: | February 12, 2025 | ||
HEARING DATE: | April 2, 2025 | ||
CONSULTANT: | Jen Flory | ||
SUBJECT: Medi-Cal: laboratory rates
SUMMARY:
Exempts clinical laboratory or laboratory services related to the diagnosis and treatment of sexually transmitted infections from the portion of the rate-setting that is based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar services. Exempts providers of these services from producing data to determine this amount and requires the remaining laboratory data to be made public.
Existing law:
- Establishes the Medi-Cal program, which is administered by the Department of Health Care Services (DHCS), and under which qualified low-income individuals receive health care services. [WIC §14000, et seq.]
- Establishes a schedule of benefits under the Medi-Cal program, which includes benefits required under federal law and benefits provided at the state’s option, both of which are funded with federal and state dollars. Includes in the schedule of benefits outpatient laboratory services, subject to utilization controls. [WIC §14132]
- Prohibits reimbursement to providers for clinical laboratory or laboratory (collectively “lab”) services from exceeding the lowest of the following: the amount billed, the amount charged to the general public, the lowest maximum allowance established by Medicare for the same or similar service, or a reimbursement rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar lab services.
[WIC §14105.22]
- Requires lab services providers to submit data reports every three years to specify the lowest amounts other payers are paying, including other state Medicaid programs and private insurance, minus discounts and rebates, for lab services. Lab providers that do not comply shall be subject to the rules regarding provider suspension from the Medi-Cal program. [WIC §14105.22]
- Authorizes DHCS to have discretion to determine the specific methodology and factors used in the development of the lowest average amount other payers are paying to ensure compliance with federal Medicaid law and regulations after seeking stakeholder input. [WIC §14105.22]
- Exempts the lab rate data submitted to DHCS from the California Public Records Act. [WIC §14105.22]
This bill:
- Exempts lab services related to the diagnosis and treatment of sexually transmitted infections (STIs) from the portion of the rate-setting that is based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar lab services.
- Exempts data on lab services related to the diagnosis and treatment of STIs from the data reporting requirements described in 1) above used in determining the lab rates.
- Requires DHCS to make available to the public a dataset of deidentified raw data that is reported pursuant to the requirement in 4) above by any applicable lab service providers that reported more than 10 tests for the data-collection period. Requires the dataset to include Healthcare Common Procedure Coding System codes, third-party payer rates, and volumes of tests furnished. Requires DHCS to publish this data when publishing the updated lab rates.
FISCAL EFFECT:
This bill has not been analyzed by a fiscal committee.
COMMENTS:
- Author’s statement. According to the author, California is experiencing epidemic levels of STIs, which left untreated, can lead to serious health complications. STIs are preventable through regular testing and timely treatment. Ensuring that these services are accessible, especially to our state’s most vulnerable populations, is critical to ending California’s STI epidemic. Unfortunately, community health centers and those that serve Medi-Cal recipients face unsustainably low reimbursement rates for STI testing, impacting their ability to provide necessary care. This bill addresses this issue by guaranteeing fair reimbursement rates for STI testing, helping to ensure that low-income Californians continue to have access to these vital services. Currently, Medi-Cal rates for STI testing are adjusted on a triannual basis based on the lowest average of commercial rate for testing, not to exceed 100% of Medicare. Intended to keep Medi-Cal costs low, the triannual review process has instead resulted in retroactive clawbacks of reimbursements and rate uncertainty, leaving community health centers scrambling to support their low-income patients. This bill will exempt STI testing and treatment from the triannual review process and cap reimbursement at the lowest maximum Medicare allowance.
- Medi-Cal Lab Reimbursement. AB 1494 (Committee on Budget, Chapter 28, Statutes of 2012), a health budget trailer bill, changed the Medi-Cal reimbursement methodology for lab services. Prior to the enactment of AB 1494, Medi-Cal reimbursement for lab services was capped at an amount that could not exceed 80% of the lowest maximum allowance established by the federal Medicare program for the same or similar services. AB 1494 stated legislative intent that DHCS develop reimbursement rates for lab services that are comparable to the payment amounts received from other payers for lab services, and capped Medi-Cal reimbursement for lab providers at an amount not to exceed the lowest of the following: the amount billed; the charge to the general public; 80% of the lowest maximum allowance established by the federal Medicare Program for the same or similar services; or, a reimbursement rate based on an average of the lowest amount that other payers and other state Medicaid programs are paying for similar lab services.
In addition to the new reimbursement methodology, AB 1494 imposed an additional Medi-Cal payment reduction of up to 10% in order to achieve General Fund savings (this reduction has not taken effect). In return, AB 1494 exempted labs from the Medi-Cal comparable price regulation for 12 months when the labs were subject to the additional 10% Medi-Cal rate reduction. Effective July 1, 2015, the new reimbursement methodology became applicable for certain lab service codes. AB 1494 required DHCS to update the reimbursement rates to the applicable lab service codes annually. To develop the new Medi-Cal lab rates, DHCS has had to collect rate data from lab providers and develop a new methodology based on those rate submissions. Both the formula and the frequency of collection of the data has been adjusted in subsequent legislation. AB 659 (Ridley Thomas, Chapter 346, Statutes of 2017) changed the frequency developing lab rates from every year to every three years. AB 133 (Committee on Budget, Chapter 143, Statutes of 2021) raised the Medicare maximum allowance threshold to 100%, though still requiring the comparisons to the amount billed, the amount charged, or the lowest average amount that other payers are paying.
According to the DHCS Clinical Laboratory Services Rate Methodology webpage, in March 2024 updated rates for 27 lab tests were posted. These rates approved on November 8, 2023, retroactive to July 1, 2023. While many of the tests are for STIs, other tests included are for drugs, tuberculosis, vitamin D, prostate cancer, surgical pathology, antibodies, thyroid function, liver function, insulin levels, other viral, bacterial, fungal, or parasite infections, and comprehensive metabolic tests to screen for diabetes, kidney, and liver disease. DHCS recently reported an update in preparation for the July 1, 2026 lab reimbursement rates, notifying over 300 providers to submit updated 2024 rates for over 300 lab procedure codes by June 30, 2025.
- Medi-Cal provider rate increases. The Medi-Cal program recently implemented some provider rate increases and is in the process of planning more due to the renewal of a Managed Care Organization (MCO) tax and Proposition 35, which passed in November 2024. Federal Medicaid regulations allow states to impose taxes on health care service providers to use as the non-federal share of spending for health care services in a state’s Medicaid program, which allows the state to draw down additional federal funding for those services. State Medicaid programs may receive federal financial participation for expenditures using health care-related taxes, as long as the taxes are broad-based, uniformly imposed, and contain no hold-harmless provisions. AB 119 (Committee on Budget, Chapter 13, Statutes of 2023) reauthorized a tax on MCOs licensed by the Department of Managed Health Care or contracted with the Medi-Cal program to generate funds for the Medi-Cal program, including to increase provider rates. Last year, the tax was increased to generate additional funding via SB 136 (Committee on Budget and Fiscal Review, Chapter 6, Statutes of 2024). In November, voters passed Proposition 35 to make the MCO tax permanent and allocate the majority of the revenues to provider rate increases. Total revenues from the tax have been estimated between $2 and $5 billion annually. Proposition 35 requires DHCS to consult with a stakeholder advisory committee, appointed by the Governor and Legislative leaders, prior to proposing or implementing any new provider payments or changes to existing provider payments supported by the MCO tax. The MCO tax does not specifically include lab rates. It does, however, contain broad categories that could include lab services, such as increases for outpatient and Family PACT program services.
- Double referral. This bill has been double referred. Should it pass out of this Committee, it will be referred to the Senate Judiciary Committee.
- Prior legislation. SB 136 (Committee on Budget and Fiscal Review, Chapter 6, Statutes of 2024) increased the existing MCO tax.
AB 119 (Committee on Budget, Chapter 13, Statutes of 2023) authorized an MCO tax, effective April 1, 2023 through December 31, 2026, with revenues to be used to support the Medi-Cal program, including new targeted provider rate increases.
AB 659 (Ridley Thomas, Chapter 346, Statutes of 2017) changed the frequency of developing lab rates from every year to every 3 years.
AB 1494 (Committee on Budget, Chapter 28, Statutes of 2012) implemented the rate methodology for lab rates as the lower of the amount billed, the amount charged to the general public, or 80% of the Medicare rate, and permitted an additional rate reduction of 10%.
- Support. Sponsors Planned Parenthood Affiliates of California write that the triannual review process was initially created to reduce Medi-Cal costs by ensuring the state does not pay above the lowest average commercial rate. However, the variable reimbursement rate this process has created actually results in a challenging financial environment for safety-net providers. The process is not transparent and is often implemented several months after the effective date, leaving providers doubly impacted - by both an unpredictable rate cut and a retroactive clawback of payments. They give the example of the most recent rate adjustment in spring 2024, where the triannual review of commercial rates for lab services, resulted in an 18% cut to the Medi-Cal rates for gonorrhea and chlamydia testing that was retroactively implemented to July 1, 2023. These revised Medi-Cal rates are 27.4% below current Medicare rates. For Planned Parenthood alone, this rate cut resulted in a greater than $10 million loss and a retroactive clawback of reimbursements for services provided between July 2023 and Spring 2024. Other supporters, including providers and consumer advocates make similar arguments about the need for stable and adequate reimbursement and point to a dramatic increase in STI rates in California in the last five years.
- Policy comment. The triennial review of lab rates is understandably a source of concern for providers of lab services due to the requirement to produce payer data, the lack of transparency of the final ratesetting, and the retroactive clawback of funding when new rates are set lower than previous rates, that can lead to considerable loss of revenue. Recently, however, the Department of Finance notified the Joint Legislative Budget Committee of a $3.44 billion loan to DHCS to pay providers due to increased 2024-2025 Medi-Cal expenditures compared to the 2024 Budget Act. DHCS has also indicated in communications to the Legislature that this amount does not cover the entire Medi-Cal shortfall, thus cuts to the Medi-Cal program are likely. Congress also appears poised to enact significant cuts to the Medicaid program over the next ten years. At the same time, discussions regarding the provider rate increases provided through the Proposition 35 stakeholder process for the distribution of MCO tax funds, are still ongoing. Given this context, resolving this problem this year outside of the MCO tax process may not be prudent.
SUPPORT AND OPPOSITION:
Support: Planned Parenthood Affiliates of California (sponsor)
American College of Obstetricians & Gynecologists – District IX
APLA Health
California Clinical Laboratory Association
California Society of Pathologists
Community Health Association Inland Southern Region
CPCA Advocates
Equality California
Los Angeles LGBT Center
Oppose: None received.
-- END --
Bill Author
Bill Co-Author(s):